Ron Epelbaum
YOU?
Author Swipe
View article: Multisite Is Superior to Single-Site Intratumoral Chemotherapy to Retard the Outcomes of Pancreatic Ductal Adenocarcinoma in a Murine Model
Multisite Is Superior to Single-Site Intratumoral Chemotherapy to Retard the Outcomes of Pancreatic Ductal Adenocarcinoma in a Murine Model Open
Introduction: Locally advanced unresectable pancreatic cancer (LAPC) has a dismal prognosis, with intratumoral therapies showing limited benefits. We assume that the dense stroma within these tumors hampers drug dispersion. Aim: This study…
View article: A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)
A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC) Open
Background: Current treatment options for PDAC patients are limited by poor survival and toxicity. Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are successful in treating several cancer types; however, PDAC remains ref…
View article: Mutant <i>KRAS</i> Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring
Mutant <i>KRAS</i> Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring Open
Background Many new pancreatic cancer treatment combinations have been discovered in recent years, yet the prognosis of pancreatic ductal adenocarcinoma (PDAC) remains grim. The advent of new treatments highlights the need for better monit…
View article: Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim <scp>PET</scp>/<scp>CT</scp> is beneficial: a prospective multicentre trial of 355 patients
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim <span>PET</span>/<span>CT</span> is beneficial: a prospective multicentre trial of 355 patients Open
Summary This multicentre study evaluated 5‐year progression‐free ( PFS ) and overall survival ( OS ) in early and advanced Hodgkin lymphoma ( HL ), where therapy was individualized based on initial prognostic factors and positron emission …
View article: Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer Open
In this retrospective analysis, the prognosis of surgically resectable BRCA-associated PDAC is no different than that of sporadic PDAC from the same institution. The role of platinum-based adjuvant therapy in this setting requires prospect…